Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;86(1):23-32.
doi: 10.1007/s00223-009-9318-7. Epub 2009 Dec 1.

Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?

Affiliations

Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?

Leila Kolios et al. Calcif Tissue Int. 2010 Jan.

Abstract

Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process. This study addressed the question of whether fracture healing in the context of osteoporosis prophylaxis is improved with estrogen (E) or alendronate (ALN). Thirty-six ovariectomized and 12 sham-operated 12-week-old rats received soy-free (osteoporotic C, sham), E-, or ALN- supplemented diets. After 10 weeks, a metaphyseal tibia osteotomy and standardized T-plate fixation were performed. After a 5-week healing process, the fracture callus was evaluated qualitatively by biomechanical bending test and quantitatively in microradiographic sections. The time course of callus formation was examined using fluorochrome-labeled histological sections. Administration of E improved the biomechanical properties of callus (stiffness [N/mm]: sham: 110.2 + or - 76.07, C: 41.28 + or - 33.70, E: 85.72 + or - 47.24, ALN: 72.07 + or - 34.68). The resistance to microfracturing seen in E-treated animals was significantly enhanced and even superior to sham (yield load [N] sham: 27.44 + or - 9.72, C: 21.04 + or - 12.47, E: 42.85 + or - 13.74(Delta), ALN: 25.28 + or - 6.4(.)) (* P < 0.05 vs. sham group, (Delta) P < 0.05 vs. C group, (*) P < 0.05 vs. E group). Trabecular bone in particular was improved, indicating the presence of physiological endosteal bridging (Tr.Dn [%] sham: 10.53 + or - 18.9, C: 1.01 + or - 0.14, E: 24.13 + or - 34.09(Delta), ALN: 3.99 + or - 8.3(.)). ALN did not help bone healing, as shown by mechanical tests. Compared to the C group, statistically, ALN did not show worse properties. The induction of callus formation under ALN treatment was slightly delayed (Tt.Cl [mm(2)] sham: 3.68 + or - 0.66, C: 3.44 + or - 0.42, E: 3.69 + or - 0.58, ALN: 3.06 + or - 0.56). Osteoporotic metaphyseal fracture healing was qualitatively and quantitatively improved by E prophylaxis. The process of fracture healing occurred nearly physiologically (shamlike). Notably, ALN hardly improved metaphyseal callus properties when assessed as osteoporosis prophylaxis, but to a lesser extent than E.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Biomechanical testing of callus formation. Stiffness was not significantly enhanced in the estrogen (E)-treated group; changes in the alendronate (ALN)-treated group did not reach sham values. Yield load in the E group was significantly improved compared to the osteoporotic C (C) group, and superior to sham group. The ALN group was slightly enhanced compared to C. P values of <0.05 were considered to be significant (* P < 0.05 vs. sham, P < 0.05 vs. C,  P < 0.05 vs. E)
Fig. 2
Fig. 2
Quantitative evaluation of microradiographic sections. Trabecular structure was significantly enhanced in the estrogen (E)-treated group compared to the osteoporotic C (C) group, surpassing levels observed in the sham group. Alendronate (ALN) was slightly improved compared to C. Callus density was enhanced under E treatment and less under ALN supplementation. P values of <0.05 were considered to be significant (* P < 0.05 vs. sham,  P < 0.05 vs. C,  P < 0.05 vs. E)
Fig. 3
Fig. 3
Intravital fluorochrome labeling. Most of the callus was created during the early, calcein green (CG)-labeled period in endosteal and dorsal regions. P values of <0.05 were considered to be significant (* value differs significantly from CG area of same group;  value differs significantly from alizarin red area of same group). The last chart presents the total callus for all stained periods
Fig. 4
Fig. 4
Corresponding microradiographic and fluorescence-labeled sections. Compared to physiological healing in the sham group, callus formation in the osteoporotic C (C) group was enhanced, but unstructured and less dense. Estrogen (E) administration induced less callus formation, but the callus present was very compact and dense, with increased amounts of trabecular structure. The alendronate (ALN) group displayed fewer and unconstrained calluses and trabeculas
Fig. 5
Fig. 5
Examples of Quantimet-based evaluation of microradiographic (a: native picture, b cortical structure, c callus areas, d trabecular structure) and fluorescence-labeled sections (a native picture, b cortical structure, c calcein green-labeled callus, d alizarin red–labeled callus, e tetracycline-labeled callus, f entire callus area)
Fig. 5
Fig. 5
Examples of Quantimet-based evaluation of microradiographic (a: native picture, b cortical structure, c callus areas, d trabecular structure) and fluorescence-labeled sections (a native picture, b cortical structure, c calcein green-labeled callus, d alizarin red–labeled callus, e tetracycline-labeled callus, f entire callus area)

Similar articles

Cited by

References

    1. Savoca S, D’Agosta S, Lombardo G. Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II. Minerva Ginecol. 2007;59:215–222. - PubMed
    1. Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA guidelines and animal models for osteoporosis. Bone. 1995;17:125–133. doi: 10.1016/8756-3282(95)97353-H. - DOI - PubMed
    1. Curtis R, Goldhahn J, Schwyn R, Regazzoni P, Suhm N. Fixation principles in metaphyseal bone—a patent based review. Osteoporos Int. 2005;16:54–64. doi: 10.1007/s00198-004-1763-6. - DOI - PubMed
    1. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349:327–334. doi: 10.1056/NEJMoa022464. - DOI - PubMed
    1. Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ. A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int. 2008;18:351–362. doi: 10.1007/s00198-006-0240-9. - DOI - PubMed

Publication types

MeSH terms